KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Equity Ratio (2016 - 2025)

Pfizer (PFE) has disclosed Equity Ratio for 17 consecutive years, with 0.43 as the latest value for Q2 2025.

  • On a quarterly basis, Equity Ratio rose 6.09% to 0.43 in Q2 2025 year-over-year; TTM through Jun 2025 was 0.43, a 6.09% increase, with the full-year FY2024 number at 0.41, up 5.28% from a year prior.
  • Equity Ratio was 0.43 for Q2 2025 at Pfizer, up from 0.41 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 2.26 in Q4 2022 to a low of 0.39 in Q4 2023.
  • A 5-year average of 0.72 and a median of 0.43 in 2025 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: surged 314.04% in 2022, then crashed 79.98% in 2023.
  • Pfizer's Equity Ratio stood at 0.43 in 2021, then soared by 314.04% to 1.77 in 2022, then plummeted by 77.74% to 0.39 in 2023, then rose by 5.28% to 0.41 in 2024, then rose by 4.35% to 0.43 in 2025.
  • Per Business Quant, the three most recent readings for PFE's Equity Ratio are 0.43 (Q2 2025), 0.41 (Q4 2024), and 0.42 (Q3 2024).